Spironolactone Tablet, Film Coated
Product Images NDC 71205-148

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Spironolactone (NDC 71205-148). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Proficient Rx Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

71205-148-30 (Spironolactone 100mg 100 Count)

Spironolactone 100 mg film coated tablets packaging label by Proficient Rx LP. The label shows a 30-count bottle containing round, biconvex, light peach to peach colored tablets with "AF" inscription on one side and a breakline on the other. Manufactured by Intas Pharmaceuticals Limited, India, this prescription oral tablet is marked with NDC 71205-148-30.*

FDA Label Image

71205-146-30 (Spironolactone 25mg 100 Count)

Label for Spironolactone 25 mg film coated tablets by Proficient Rx LP with an NDC of 71205-146-30. The label states quantity as 30 tablets and details the tablet as light yellow to yellow, round, biconvex with an "AD" imprint on one side and plain on the other, with a faint peppermint odor. Manufacturer is Intas Pharmaceuticals Limited, India. Storage instructions and warnings about keeping medication out of reach of children are included.*

FDA Label Image

71205-147-30 (Spironolactone 50mg 100 Count)

Label for Spironolactone 50 mg film coated tablets by Proficient Rx LP. The label states the product contains 30 tablets, each with 50 mg of Spironolactone USP. Tablets are described as light orange to orange, oval, biconvex with an 'AE' inscription and peppermint odor. The manufacturer is Intas Pharmaceuticals Limited, India, with storage instructions at 20°-25°C. Includes lot, expiration, and barcode details.*

FDA Label Image

Figure 1. Survival By Treatment Group In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 1)

A Kaplan-Meier survival curve comparing the probability of an event over time in months for a clinical study cohort treated with spironolactone versus placebo. The chart shows two lines representing the cumulative probability with sample sizes of 822 for spironolactone and 841 for placebo along with a log-rank p-value of less than 0.001.*

FDA Label Image

Figure 2. Hazard Ratios Of All-cause Mortality By Subgroup In The Randomized Spironolactone Evaluation Study (Spironolactone Figure 2)

A forest plot displaying hazard ratios (HR) and 95% confidence intervals (CI) for various subgroups in a clinical study. The subgroups include age, sex, race, left ventricular ejection fraction (LVEF), heart failure type, NYHA classification, diabetes status, serum creatinine, creatinine clearance, potassium levels, digoxin use, ACE inhibitor use, and beta blocker use. The plot compares Spironolactone versus placebo efficacy, with HR values indicated by squares and confidence intervals shown as horizontal lines.*

FDA Label Image

Chemical Structure (Spironolactone Structure Image)

Chemical structure of spironolactone, the active ingredient in Spironolactone tablets, shown as a detailed molecular diagram with labeled functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.